Page last updated: 2024-10-26

ebselen and Plasmacytoma

ebselen has been researched along with Plasmacytoma in 1 studies

ebselen : A benzoselenazole that is 1,2-benzoselenazol-3-one carrying an additional phenyl substituent at position 2. Acts as a mimic of glutathione peroxidase.

Plasmacytoma: Any discrete, presumably solitary, mass of neoplastic PLASMA CELLS either in BONE MARROW or various extramedullary sites.

Research Excerpts

ExcerptRelevanceReference
"Treatment with ebselen did not reduce the antitumor activity of cisplatin against MPC 11 plasmacytoma or Prima breast tumor in BALB/c mice."1.28Selective reduction of cis-diamminedichloroplatinum(II) nephrotoxicity by ebselen. ( Baldew, GS; de Goeij, JJ; Los, G; McVie, JG; van der Valk, MA; Vermeulen, NP, 1990)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Baldew, GS1
McVie, JG1
van der Valk, MA1
Los, G1
de Goeij, JJ1
Vermeulen, NP1

Other Studies

1 other study available for ebselen and Plasmacytoma

ArticleYear
Selective reduction of cis-diamminedichloroplatinum(II) nephrotoxicity by ebselen.
    Cancer research, 1990, Nov-01, Volume: 50, Issue:21

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Azoles; Cisplatin; Drug Adm

1990